No immediate trading catalyst. Monitor future equity grant activity under the expanded plan for potential dilution. The filing confirms routine corporate governance and no changes to executive team or strategy.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 16 $110.12entry
- T+1 · 5mo ago +2.28%α +3.53% · $112.63
- T+5 · 5mo ago +7.77%α +10.01% · $118.68
- T+20 · 4mo ago +35.92%α +35.72% · $149.68
- T+60 · 2mo ago +36.57%α +35.57% · $150.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palvella Therapeutics held its 2026 Annual Meeting on June 10, 2026, where shareholders approved an amendment to the 2024 Equity Incentive Plan to increase authorized shares by 750,000 (approximately 5.2% of outstanding shares). All director nominees were elected, Ernst & Young was ratified as auditor, and advisory votes on executive compensation and frequency were approved. This is a routine governance filing with no material financial or operational impact.
Key Facts
- Shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing authorized shares by 750,000.
- Class III directors George M. Jenkins, Todd C. Davis, and John Doux, M.D. were elected with strong support.
- Ernst & Young LLP was ratified as independent auditor for fiscal 2026 with 11,557,687 votes for.
- Advisory vote on named executive officer compensation passed with 10,008,180 votes for.
- Board determined to hold advisory say-on-pay votes annually based on shareholder preference.
- Plan amendment became effective immediately upon stockholder approval on June 10, 2026.
Financial Impact
No immediate financial impact. The 750,000 share increase represents potential future dilution of ~5.2% of current outstanding shares (14,323,686) through equity grants.
Risk Factors
- Potential dilution from future equity awards under the expanded plan.
- No material operational or financial updates in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-074338 |
| Document: tm2618003d1_ex10-1.htm | 0001104659-26-074338 |
| Document: 0001104659-26-074338-index-headers.html | 0001104659-26-074338 |
| Document: 0001104659-26-074338-index.html | 0001104659-26-074338 |
| Document: 0001104659-26-074338.txt | 0001104659-26-074338 |
Track record
36 reports on PVLA
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers